Tofersen, a New Treatment for A.L.S., Reverses Symptoms for Some
The drug is for a small subset of patients. But [...]
Ipsen has set aside the two drug…
Ipsen has set aside the two drug candidates it picked [...]
The company announced it has…
The company announced it has concluded development of the plasma [...]
GSK has found another potential…
GSK has found another potential way to treat cardiometabolic disease [...]
With Gilead’s $7.8 billion buyout…
With Gilead’s $7.8 billion buyout of Arcellx complete, the California [...]
With a better-than-expected first…
With a better-than-expected first quarter in the books, Pfizer—continuing to [...]
Novartis is continuing its…
Novartis is continuing its multiyear overhaul with new plans to [...]
The German vaccine maker plans to…
The German vaccine maker plans to wind down operations at [...]
Madrigal Pharmaceuticals has…
Madrigal Pharmaceuticals has struck a backloaded deal for the global [...]
Pfizer’s $2.3 billion bet on…
Pfizer’s $2.3 billion bet on Trillium Therapeutics doesn’t look like [...]